Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (dkfz), Heidelberg, Germany.
Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, Germany.
Clin Cancer Res. 2016 Jan 1;22(1):9-15. doi: 10.1158/1078-0432.CCR-15-0820.
Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical challenge. Because the prostate-specific membrane antigen (PSMA) is frequently overexpressed in prostate cancer, several PSMA-targeting molecules are under development to detect and treat metastatic castration-resistant prostate cancer (mCRPC). mCRPC represents a situation where cure is no longer achievable and novel therapeutic approaches for palliation and increase of survival are needed. In this article, we discuss the recent development for noninvasive detection of recurrent disease and therapy of mCRPC with corresponding PSMA-targeted radioligands.
前列腺癌患者的关键问题是检测复发疾病和治疗转移性癌症。早期检测是所有常规成像方式的主要挑战。此外，激素抵抗性肿瘤病变患者的治疗也是一个重大的临床挑战。由于前列腺特异性膜抗原（PSMA）在前列腺癌中经常过度表达，因此正在开发几种针对 PSMA 的分子来检测和治疗转移性去势抵抗性前列腺癌（mCRPC）。mCRPC 代表一种无法治愈的情况，需要新的治疗方法来缓解症状和提高生存率。在本文中，我们讨论了使用相应的 PSMA 靶向放射性配体进行非侵入性检测复发疾病和治疗 mCRPC 的最新进展。
